Keyphrases
Tapentadol
100%
Moderate to Severe Pain
100%
Immediate Release
44%
Tapentadol Prolonged Release
44%
Moderate to Severe
33%
Clinical Trials
22%
Opioids
22%
Extended Release
22%
Acute Pain
22%
Oxycodone
22%
Opioid Analgesics
22%
Opioid Agonist
22%
United States
11%
Tolerability
11%
Cognitive Impairment
11%
Postoperative Pain
11%
Active Metabolite
11%
Disability
11%
Quality of Life
11%
Chronic Pain
11%
Synergistic Effect
11%
Painful Diabetic Neuropathy
11%
Controlled Release
11%
Sedative
11%
U.S. Food
11%
Patient Report
11%
Pain Relief
11%
Dizziness
11%
Low Affinity
11%
Opioid Side Effects
11%
Dual-acting
11%
Severe Acute
11%
Renal Failure
11%
μ-Opioid Receptor Agonist
11%
Nausea
11%
Vomiting
11%
Twice-daily Dosing
11%
Over 80
11%
Illicit Drugs
11%
Respiratory Depression
11%
Somnolence
11%
Muscle Relaxant
11%
Monoamine Oxidase Inhibitors
11%
Hepatic Failure
11%
Postoperative Patients
11%
Severe Chronic Pain
11%
Anxiolytic
11%
Central Analgesic
11%
Gastrointestinal Tolerability
11%
Central Nervous System Depressants
11%
Gastrointestinal Side Effects
11%
Gastrointestinal
11%
Norepinephrine Levels
11%
Over-reliance
11%
Serotonin-norepinephrine Reuptake Inhibitors
11%
Intolerability
11%
Pharmacology, Toxicology and Pharmaceutical Science
Tapentadol
100%
Opiate
30%
Clinical Trial
15%
Tablet
15%
Tolerability
15%
Pain
15%
Side Effect
15%
Analgesic Agent
15%
Chronic Pain
15%
Opiate Agonist
15%
Oxycodone
15%
Antipsychotic
7%
Controlled Release
7%
Norepinephrine Reuptake Inhibitor
7%
Active Metabolite
7%
Cognitive Defect
7%
Diabetic Neuropathy
7%
Postoperative Pain
7%
Adverse Event
7%
Noradrenalin
7%
Kidney Failure
7%
Nausea
7%
Dizziness
7%
Mu Opiate Receptor Agonist
7%
Illicit Drug
7%
Liver Failure
7%
Muscle Relaxant Agent
7%
Respiration Depression
7%
Anxiolytic
7%
Monoamine Oxidase Inhibitor
7%
Central Depressant Agent
7%
Somnolence
7%